復星醫藥(600196.SH):子公司擬與關聯方共設私募股權投資基金
格隆匯1月24日丨復星醫藥(600196.SH)公佈,公司控股子公司/企業星盛復盈、寧波復瀛與關聯方復星高科技及其他投資人擬共同出資設立目標基金;其中:星盛復盈(作為GP)、寧波復瀛(作為LP)、復星高科技(作為LP)擬分別以現金出資人民幣300萬元、6600萬元、4400萬元認繳目標基金中的等值財產份額。
目標基金將主要參股投資生物醫藥和醫療健康行業領域內早期企業。目標基金首期計劃募集資金人民幣1.76億元。目標基金設立完成後,擬聘任公司控股子公司復健基金管理公司為目標基金的基金管理人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.